The Program in Hematopoietic Cell Transplantation and Immune Reconstitution is a multidisciplinary effort aimed at developing a better understanding of the biological mechanisms underlying both autologous and allogeneic hematopoietic cell transplantation (HCT). Major themes of research include developing mechanistic insights into the underlying principles of stem cell engraftment, graft vs. host disease, graft vs. tumor reactions and immune reconstitution. Translation of novel concepts to the clinic derived from these more basic studies is of central importance. These goals are achieved by engaging a dynamic group of 19 investigators from four Departments supported by Program Project (two POls), investigator initiated (17 ROls), clinical trials network (U01), training (T32 and three K awards) and Foundation grants. Using the concept of translational research where new concepts and ideas are developed in the laboratory and extended to the clinic, as well as insights from the clinic with extension to the laboratory, novel avenues of research and strategies for intervention have been and continue to be explored. Since 2000, over 180 publications relevant to the goals of the Program have been published in peer-reviewed journals. This Program enlists basic scientists, physician-scientists and clinician investigators centered upon the over-riding goal of improving outcomes for patients undergoing HCT. Our vision is to explore the major mechanisms of successful transplantation including engraftment of hematopoietic stem cells, graft-vs.-tumor and graft-vs.-host reactions and enhancement of immune reconstitution through laboratory-based projects with extension to the clinic through mainly investigator initiated clinical trials. Clinical strategies have and are being developed based upon laboratory investigations to probe mechanisms of the major cellular populations including hematopoietic stem cells, myeloid and lymphoid progenitor cells, NK, T, NK-T and antigen presenting cells. This Program extensively interacts with both basic and translational investigators from a number of different Programs and is supported by all Cancer Center Shared Resources to provide a rich fabric of discovery and clinical translation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-03
Application #
7826893
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
3
Fiscal Year
2009
Total Cost
$20,909
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications